Viewpoints

Monoclonal antibodies (mAbs) are lab-engineered proteins that mimic the ability of the immune system to neutralize harmful pathogens. Produced by identical immune cells cloned from a single parent cell, these antibodies target a specific antigen with high precision. Their applications span across medicine, treating cancers, autoimmune disorders, and infectious diseases, as well as diagnostics and research.

From ‘Pharmacy of the World’ to becoming the preferred outsourcing destination for innovative scientific solutions, India’s Life Science industry has seen a dramatic shift. Driving this change is the contract research development manufacturing organization (CRDMO) industry, which witnessed a CAGR of 15% between 2019 and 24, double the global growth rate of 7%–8%.

Learn about GLP-1 peptides and their revolutionary impact on modern medicine, and how Syngene is enabling this advancement through its state-of-the-art peptide synthesis facility.

Learn about the challenges in chemical derivatization and utilizing LC-MS/MS to detect and quantify trace compounds in complex molecules for supporting bioanalytical studies.

Learn about the various challenges in developing LAIs and the technologies and techniques being used by Syngene to help clients use this transformative drug delivery system to treat chronic diseases.

Explore the top challenges in developing CAR-T therapy for treating cancer and how leading CRO-CDMO Syngene supports clients in bringing this therapy to patients faster.

Learn the rigorous measures established at Syngene for tissue procurement, iPSC reprogramming, systematic cell banking, inventory management, and quality control of every iPSC batch to maximize drug discovery success.

Learn the simple and complex connections that must be established for successful large molecule bioanalytical sample analysis supporting clinical trials.

Learn the key strategies adopted by leading CDMO Syngene to accelerate the lead to first-in-human (FIH) journey of small molecules for clients.

Learn the challenges in the detection and quantitation of process-related impurities, including nitrosamine and azido impurities, and Syngene’s capabilities and solutions to resolve them.